# LeMaitre Vascular, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/LeMaitre Vascular, Inc). ## Overview LeMaitre Vascular Inc. develops, manufactures, and sells specialized vascular devices and human tissue cryopreservation services used mainly in open vascular surgery and dialysis access. Built through a long series of acquisitions and internal development, the company has assembled a portfolio of branded products for treating peripheral vascular disease, end-stage renal disease, and related cardiovascular conditions. ## Products & services • Biologic vascular products: XenoSure, CardioCel, VascuCel, Artegraft • Synthetic and biosynthetic grafts: Omniflow II, polyester, ePTFE, polycarbonate grafts • Surgical devices: valvulotomes, embolectomy catheters, shunts, vessel closure systems • Specialty tools: angioscopes, contrast injectors, remote endarterectomy devices • Human tissue cryopreservation and processing services via RestoreFlow - **Biologic vascular products** (53%) — Bovine, ovine, human tissue, and other biologic patches and grafts used in vascular and cardiac repair. - **Synthetic and biosynthetic grafts** (17%) — Polyester, ePTFE, polycarbonate, and hybrid graft products used in vascular reconstruction. - **Surgical instruments and access devices** (20%) — Valvulotomes, embolectomy catheters, shunts, closure systems, and related open-surgery tools. - **Specialty imaging and procedure tools** (5%) — Angioscopes, contrast injectors, and other adjunct devices used during vascular procedures. - **Human tissue cryopreservation services** (5%) — RestoreFlow processing, preservation, and cryopreservation services for human vascular and cardiac tissue. - Biologic patches and grafts for vascular and cardiac procedures - Synthetic and biosynthetic grafts for arterial and venous repair - Valvulotomes, embolectomy catheters, and shunts for open surgery - Angioscopes, contrast injectors, and endarterectomy tools - Human tissue cryopreservation and allograft processing services ## Customers The core customer is the vascular surgeon, who buys LeMaitre products for open vascular surgery and dialysis access procedures. The company also sells selected products to cardiac surgeons, general surgeons, neurosurgeons, and, to a lesser degree, interventional cardiologists as it expands beyond its original call point. Hospitals, clinics, and distributors are the purchasing channels, with direct sales representatives handling most territories. - **Vascular surgeons** (primary) — Primary call point buying valvulotomes, grafts, catheters, and patches for peripheral vascular disease and dialysis access. - **Hospitals and clinics** (primary) — End customers and care settings that purchase the devices and services for surgical use, often via direct sales or consignment. - **Cardiac surgeons** (secondary) — Buy biologic patches and cryopreservation-related products such as RestoreFlow and CardioCel for cardiac applications. - **Distributors** (secondary) — Purchase in markets without direct sales coverage and resell into hospitals and clinics. - **Other surgical specialties** (emerging) — General surgeons and neurosurgeons buy selected niche products where the portfolio fits their procedures. - Vascular surgeons buying branded tools and grafts for open procedures - Cardiac surgeons using RestoreFlow and CardioCel products - Hospitals and clinics purchasing through direct sales or consignment - Distributors in countries without direct sales coverage - Dialysis access providers needing biologic and synthetic grafts ## Geography LeMaitre sells globally, with principal markets in the United States, Europe, Canada, and Asia Pacific. About 43% of 2025 sales occurred outside the United States, and roughly 95% of net sales were generated in territories covered by direct sales representatives, which makes field coverage a key driver of growth and pricing power. The company also operates regional headquarters and sales offices in Europe and Asia Pacific, while manufacturing is concentrated in the United States with one key third-party supply relationship in Germany. - United States is the largest market and home to headquarters and most manufacturing - Europe is a major sales region with headquarters in Germany and multiple local offices - Asia Pacific is served from Singapore with offices across Japan, China, Korea, Australia, and Thailand - Canada has a North American sales office in Vaughan, supporting regional coverage - About 43% of 2025 sales were outside the United States, increasing FX exposure ## Strategy LeMaitre’s strategy is to deepen its focus on niche vascular products, expand direct sales coverage, and add complementary products through acquisitions. Management also aims to grow in adjacent call points and new countries while maintaining a portfolio mix that is less dependent on any single product line. - **Acquire complementary vascular products** (medium-term) — Acquisitions have been a primary growth engine and broaden the portfolio without relying on one product. - **Expand direct sales internationally** (short-term) — Direct coverage supports pricing, surgeon relationships, and market penetration in new countries. - **Grow biologic and adjacent-call-point products** (medium-term) — Biologic offerings are a large share of sales and can extend the company beyond the core vascular surgeon base. - Use acquisitions to broaden the vascular portfolio and add adjacent products - Expand direct-to-hospital sales in new countries to improve market access - Focus on low-rivalry niche products where brand and surgeon relationships matter - Cross-sell biologic products into cardiac surgery and other adjacent call points - Maintain manufacturing control in-house where possible to support quality and supply ## Risks The business depends on a narrow set of specialized medical procedures, so competitive pressure, reimbursement changes, and shifts toward endovascular techniques can erode demand for open-surgery products. Growth also depends on acquisitions, regulatory approvals, and reliable sourcing of biologic and tissue-based inputs, while international exposure creates foreign exchange, compliance, and distributor risks. - **Competitive pressure and procedure mix shift** [high] — Open vascular products compete with endovascular devices and larger rivals with broader resources. - **Acquisition execution risk** [high] — A meaningful part of growth has come from acquisitions, which may be harder to source or integrate. - **Foreign exchange volatility** [medium] — A large share of sales is outside the U.S. and denominated in foreign currencies. - **Supply and donor tissue constraints** [high] — Biologic and cryopreservation products rely on limited-source suppliers and tissue availability. - **Regulatory and product liability exposure** [high] — Medical devices and human tissue services face FDA, foreign regulatory, and liability risk. - Competition from larger device makers and endovascular alternatives can pressure share and pricing - Acquisition-led growth may slow if targets are unavailable or integrations underperform - Foreign exchange moves can affect reported sales because much of the business is non-U.S. - Biologic and tissue products depend on limited-source suppliers and donor tissue availability - Cybersecurity, ERP implementation, and regulatory compliance can disrupt operations ## Accounting Revenue is recognized when control transfers, but returns, invoice adjustments, and consignment timing can affect reported sales in a given period. Management also uses judgment for acquisition-related contingent consideration, inventory and deferred costs, and the valuation of liabilities tied to future earn-outs, all of which can move operating income and balance sheet values. - **Revenue recognition and returns reserve** — Can shift quarterly revenue and gross margin - **Contingent consideration from acquisitions** — Can create operating income volatility - **Inventory and deferred cost estimates** — Affects cost of sales and asset carrying values - **Foreign currency translation** — Affects reported revenue and operating results - Revenue recognition depends on transfer of control and consignment usage timing - Sales returns and allowances require estimates that affect net revenue - Acquisition earn-outs are remeasured each period and can move operating income - Inventory and deferred cost estimates affect margins and asset values - Foreign currency translation affects reported sales from non-U.S. operations --- *Last updated: 2026-04-28T20:21:12.498752+00:00*